The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity
Open accessAbstract
To generate chimeric Ag receptors (CARs) for the adoptive immunotherapy of cancer patients with ErbB2-expressing tumors, a single-chain Ab derived from the humanized mAb 4D5 Herceptin (trastuzumab) was initially linked to T cell signaling domains derived from CD28 and the CD3ζ to generate a CAR against ErbB2. Human PBLs expressing the 4D5 CAR demonstrated Ag-specific activities against ErbB2+ tumors. However, a gradual loss of transgene expression was noted for PBLs transduced with this 4D5 CAR. When the CD3ζ signaling domain of the CAR was truncated or mutated, loss of CAR expression was not observed, suggesting that the CD3ζ signaling caused the transgene decrease, which was supported by the finding that T cells expressing 4D5 CARs with CD3ζ ITAM mutations were less prone to apoptosis. By adding 4-1BB cytoplasmic domains to the CD28-CD3ζ signaling moieties, we found increased transgene persistence in 4D5 CAR-transduced PBLs. Furthermore, constructs with 4-1BB sequences demonstrated increased cytokine secretion and lytic activity in 4D5 CAR-transduced T cells. More importantly, PBLs expressing this new version of the 4D5 CAR could not only efficiently lyse the autologous fresh tumor digests, but they could strongly suppress tumor growth in a xenogenic mouse model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Self-citationCancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Self-citationHumanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Self-citationEshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Self-citationDudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Self-citationTumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
Self-citationTNF/TNFR FAMILY MEMBERS IN COSTIMULATION OF T CELL RESPONSES
Watts, T. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115839 · Cited by 1,353
Roles of the NKG2D immunoreceptor and its ligands
Raulet, D. H. (2003) · Nature Reviews Immunology · doi:10.1038/nri1199 · Cited by 1,348
Dudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,332
Self-citationA Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Self-citationPule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Self-citationLamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 898
Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?
Croft, M. (2003) · Nature Reviews Immunology · doi:10.1038/nri1148 · Cited by 863
Tan-Chiu, E., Yothers, G., Romond, E., Geyer, C. E., Ewer, M., Keefe, D., Shannon, R. P., Swain, S. M., Brown, A., Fehrenbacher, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4091 · Cited by 808
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
Press, M. F., Cordon‐Cardo, C., & Slamon, D. J. (1990) · PubMed · Cited by 638
Park, J. R., DiGiusto, D. L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet, H. B., Bautista, C., Chang, W.-C., Ostberg, J. R., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300104 · Cited by 603
A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens
Rosenberg, S. A. (1999) · Immunity · doi:10.1016/s1074-7613(00)80028-x · Cited by 566
Self-citationTargeting tumours with genetically enhanced T lymphocytes
Sadelain, M., Rivière, I., & Brentjens, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc971 · Cited by 535
Self-citationTumor-specific cytolysis by lymphocytes infiltrating human melanomas.
Topalian, S. L., Solomon, D., & Rosenberg, S. A. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.10.3714 · Cited by 512
Self-citationAlexander-Miller, M. A., Leggatt, G. R., & Berzofsky, J. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4102 · Cited by 501
Finney, H. M., Akbar, A. N., & Lawson, A. D. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.104 · Cited by 467
Maus, M. V., Thomas, A. K., Leonard, D. G. B., Allman, D., Addya, K., Schlienger, K., Riley, J. L., & June, C. H. (2002) · Nature Biotechnology · doi:10.1038/nbt0202-143 · Cited by 454
Disis, M. L., Gooley, T. A., Rinn, K., Davis, D., Piepkorn, M., Cheever, M. A., Knutson, K. L., & Schiffman, K. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.171 · Cited by 423
Clay, T. M., Custer, M. C., Sachs, J., Hwu, P., Rosenberg, S. A., & Nishimura, M. I. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.507 · Cited by 410
Self-citationThe Makings of a Tumor Rejection Antigen
Gilboa, E. (1999) · Immunity · doi:10.1016/s1074-7613(00)80101-6 · Cited by 381
Cutting Edge: 4-1BB Is a Bona Fide CD8 T Cell Survival Signal
Takahashi, C., Mittler, R. S., & Vella, A. T. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.9.5037 · Cited by 379
High Avidity CTLs for Two Self-Antigens Demonstrate Superior In Vitro and In Vivo Antitumor Efficacy
Zeh, H. J., Perry-Lalley, D., Dudley, M. E., Rosenberg, S. A., & Yang, J. C. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.2.989 · Cited by 376
Self-citation4-1BB Promotes the Survival of CD8+ T Lymphocytes by Increasing Expression of Bcl-xL and Bfl-1
Lee, H.-W., Park, S.-J., Choi, B. K., Kim, H. H., Nam, K.-O., & Kwon, B. S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.4882 · Cited by 363
Cannons, J. L., Lau, P., Ghumman, B., DeBenedette, M. A., Yagita, H., Okumura, K., & Watts, T. H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1313 · Cited by 355
4-1BB-mediated immunotherapy of rheumatoid arthritis
Seo, S. K., Choi, J. H., Kim, Y. H., Kang, W. J., Park, H. Y., Suh, J. H., Choi, B. K., Vinay, D. S., & Kwon, B. S. (2004) · Nature Medicine · doi:10.1038/nm1107 · Cited by 325
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice
McNamara, J. O., Kolonias, D., Pastor, F., Mittler, R. S., Chen, L., Giangrande, P. H., Sullenger, B., & Gilboa, E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33365 · Cited by 310
Stephan, M. T., Ponomarev, V., Brentjens, R. J., Chang, A. H., Dobrenkov, K. V., Heller, G., & Sadelain, M. (2007) · Nature Medicine · doi:10.1038/nm1676 · Cited by 299
Self-citationImmunotherapy through TCR gene transfer
Kessels, H. W. H. G., Wolkers, M. C., van den Boom, M. D., van den Valk, M. A., & Schumacher, T. N. M. (2001) · Nature Immunology · doi:10.1038/ni1001-957 · Cited by 279
Chmielewski, M., Hombach, A., Heuser, C., Adams, G. P., & Abken, H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7647 · Cited by 260
Wilcox, R. A., Flies, D. B., Zhu, G., Johnson, A. J., Tamada, K., Chapoval, A. I., Strome, S. E., Pease, L. R., & Chen, L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14184 · Cited by 259
Hurtado, J. C., Kim, Y. J., & Kwon, B. S. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.2600 · Cited by 257
Hughes, M. S., Yu, Y. Y. L., Dudley, M. E., Zheng, Z., Robbins, P. F., Li, Y., Wunderlich, J., Hawley, R. G., Moayeri, M., Rosenberg, S. A., et al. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.457 · Cited by 231
Self-citationNicholson, I. C., Lenton, K. A., Little, D. J., Decorso, T., Lee, F. T., Scott, A. M., Zola, H., & Hohmann, A. W. (1997) · Molecular Immunology · doi:10.1016/s0161-5890(97)00144-2 · Cited by 226
Wilcox, R. A., Flies, D. B., Zhu, G., Johnson, A. J., Tamada, K., Chapoval, A. I., Strome, S. E., Pease, L. R., & Chen, L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214184 · Cited by 222
Zhao, Y., Bennett, A. D., Zheng, Z., Wang, Q. J., Robbins, P. F., Yu, L. Y. L., Li, Y., Molloy, P. E., Dunn, S. M., Jakobsen, B. K., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.5845 · Cited by 220
Self-citationTargeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.
Stancovski, I., Schindler, D. G., Waks, T., Yarden, Y., Sela, M., & Eshhar, Z. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.11.6577 · Cited by 216
Self-citationPeoples, G. E., Gurney, J. M., Hueman, M. T., Woll, M. M., Ryan, G. B., Storrer, C. E., Fisher, C., Shriver, C. D., Ioannides, C. G., & Ponniah, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.047 · Cited by 216
Wang, J., Jensen, M., Lin, Y., Sui, X., Chen, E., Lindgren, C. G., Till, B., Raubitschek, A., Forman, S. J., Qian, X., et al. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.028 · Cited by 213
Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells.
Moritz, D., Wels, W., Mattern, J., & Groner, B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4318 · Cited by 208
Wen, T., Bukczynski, J., & Watts, T. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.10.4897 · Cited by 207
Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition?
Vivier, E., Tomasello, E., & Paul, P. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00337-0 · Cited by 204
Zhang, H., Snyder, K. M., Suhoski, M. M., Maus, M. V., Kapoor, V., June, C. H., & Mackall, C. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4910 · Cited by 202
Zhao, Y., Zheng, Z., Robbins, P. F., Khong, H. T., Rosenberg, S. A., & Morgan, R. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.4415 · Cited by 191
Self-citationLu, D., Shen, J., Vil, M. D., Zhang, H., Jimenez, X., Bohlen, P., Witte, L., & Zhu, Z. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307742200 · Cited by 183
Gurney, J. M., Hueman, M. T., Woll, M. M., Ryan, G. B., Storrer, C. E., Fisher, C., Shriver, C. D., Ioannides, C. G., Ponniah, S., & Peoples, G. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2575 · Cited by 183
Foell, J. L., Strahotin, S., O’Neil, S. P., McCausland, M. M., Suwyn, C. R., Haber, M., Chander, P. N., Bapat, A. S., Yan, X., Chiorazzi, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17662 · Cited by 176
Sabbagh, L., Pulle, G., Liu, Y., Tsitsikov, E. N., & Watts, T. H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.12.8093 · Cited by 167
The 4-1BB Costimulation Augments the Proliferation of CD4+CD25+ Regulatory T Cells
Zheng, G., Wang, B., & Chen, A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2428 · Cited by 164
Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB
Ye, Z., Hellström, I., Hayden-Ledbetter, M. S., Dahlin, A., Ledbetter, J. A., & Hellström, K. E. (2002) · Nature Medicine · doi:10.1038/nm0402-343 · Cited by 156
Elpek, K. G., Yolcu, E. S., Franke, D. D. H., Lacelle, C., Schabowsky, R.-H., & Shirwan, H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7295 · Cited by 154
Bernhard, H., Neudorfer, J., Gebhard, K., Conrad, H., Hermann, C., Nährig, J., Fend, F., Weber, W., Busch, D. H., & Peschel, C. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0355-7 · Cited by 146
Hippen, K. L., Harker-Murray, P. D., Porter, S. B., Merkel, S. C., Londer, A., Taylor, D. K., Bina, M., Panoskaltsis‐Mortari, A., Rubinstein, P., van Rooijen, N., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132951 · Cited by 144
May, K. F., Chen, L., Zheng, P., & Liu, Y. (2002) · PubMed · Cited by 122
The T-Body Approach: Redirecting T Cells with Antibody Specificity
Eshhar, Z. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_14 · Cited by 111
Self-citationBukczynski, J., Wen, T., Ellefsen, K., Gauldie, J., & Watts, T. H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306567101 · Cited by 109
UpGene: Application of a Web‐Based DNA Codon Optimization Algorithm
Gao, W., Rzewski, A., Sun, H., Robbins, P. D., & Gambotto, A. A. (2004) · Biotechnology Progress · doi:10.1021/bp0300467 · Cited by 109
Kmieciak, M., Knutson, K. L., Dumur, C. I., & Manjili, M. H. (2007) · European Journal of Immunology · doi:10.1002/eji.200636639 · Cited by 108
Lamers, C. H. J., Langeveld, S. C. L., Ruijven, C. M. G.-V., Debets, R., Sleijfer, S., & Gratama, J. W. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0330-3 · Cited by 94
Combadière, B., Freedman, M. L., Chen, L., et al. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.5.2109 · Cited by 92
Pinthus, J. H., Waks, T., Kaufman‐Francis, K., Schindler, D. G., Harmelin, A., Kanety, H., Ramon, J., & Eshhar, Z. (2003) · PubMed · Cited by 88
Self-citationFriedmann‐Morvinski, D., Bendavid, A., Waks, T., Schindler, D., & Eshhar, Z. (2004) · Blood · doi:10.1182/blood-2004-09-3737 · Cited by 84
Self-citationGene-Engineered T Cells as a Superior Adjuvant Therapy for Metastatic Cancer
Kershaw, M. H., Jackson, J. T., Haynes, N. M., Teng, M. W. L., Moeller, M., Hayakawa, Y., Street, S. E. A., Cameron, R., Tanner, J. E., Trapani, J. A., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.3.2143 · Cited by 83
Costimulation of human CD28– T cells by 4‐1BB ligand
Bukczynski, J., Wen, T., & Watts, T. H. (2003) · European Journal of Immunology · doi:10.1002/immu.200310020 · Cited by 72
Gene modification strategies to induce tumor immunity.
Murphy, A., Westwood, J. A., Teng, M., Moeller, M., Darcy, P., & Kershaw, M. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.007 · Cited by 70
Lee, J., Lee, E.-N., Kim, E. Y., Park, H.-J., Chang, C.-Y., Jung, D.-Y., Choi, S.-Y., Lee, S., Lee, K.-W., Kwon, G.-Y., et al. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.06.001 · Cited by 58
Zhou, J., Dudley, M. E., Rosenberg, S. A., & Robbins, P. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7622 · Cited by 52
Self-citationModulation of the Immune Response Through 4-1BB
Sica, G., & Chen, L. (2002) · Advances in experimental medicine and biology · doi:10.1007/0-306-46817-4_30 · Cited by 44
Signatures Associated with Rejection or Recurrence in HER-2/ neu –Positive Mammary Tumors
Worschech, A., Kmieciak, M., Knutson, K. L., Bear, H. D., Szalay, A. A., Wang, E., Marincola, F. M., & Manjili, M. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6822 · Cited by 42
4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cells
Kim, Y., Han, M., & Broxmeyer, H. E. (2007) · Blood · doi:10.1182/blood-2007-01-069450 · Cited by 26
Cited by
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Self-citationLong, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Tumor Antigen Escape from CAR T-cell Therapy
Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,183
Parkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
Self-citationZhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843
Self-citation
Metadata
- Authors
- Zhao, Y., Wang, Q. J., Yang, S., Kochenderfer, J. N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S. A., & Morgan, R. A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-11-01
- Volume
- 183
- Issue
- 9
- Pages
- 5563-5574
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1842126375
- Cited by
- 293
- References
- 79
- FWCI
- 8.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.